{
    "organizations": [],
    "uuid": "8194b8a98cc4a65d32bafa1101938f42c84379d0",
    "author": "",
    "url": "https://www.reuters.com/article/brief-promis-neurosciences-product-candi/brief-promis-neurosciences-product-candidate-for-alzheimers-disease-shows-potential-for-improved-therapeutic-potency-idUSFWN1PI0SY",
    "ord_in_thread": 0,
    "title": "BRIEF-Promis Neurosciences Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 51 PM / in 10 minutes BRIEF-Promis Neurosciences Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency Reuters Staff 1 Min Read \nJan 23 (Reuters) - Promis Neurosciences Inc: \n* PROMIS NEUROSCIENCES LEAD PRODUCT CANDIDATE FOR ALZHEIMER‘S DISEASE SHOWS POTENTIAL FOR IMPROVED THERAPEUTIC POTENCY VERSUS OTHER AMYLOID BETA-DIRECTED ANTIBODIES \n* PROMIS - ‍IN COMPARISON TO ADUCANUMAB, PMN310 SHOWED SIGNIFICANTLY GREATER BINDING TO BRAIN MATERIAL FROM AD PATIENTS WITH TOXIC AΒ OLIGOMERS​ \n* PROMIS NEUROSCIENCES INC - “‍AFFINITY MATURATION OF PMN310 IS ONGOING AND MAY RESULT IN AN EVEN GREATER ADVANTAGE WITH PMN310”​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-23T14:50:00.000+02:00",
    "crawled": "2018-01-23T15:09:20.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "neuroscience",
        "product",
        "candidate",
        "alzheimer",
        "disease",
        "show",
        "potential",
        "improved",
        "therapeutic",
        "potency",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "promis",
        "neuroscience",
        "inc",
        "promis",
        "neuroscience",
        "lead",
        "product",
        "candidate",
        "alzheimer",
        "disease",
        "show",
        "potential",
        "improved",
        "therapeutic",
        "potency",
        "versus",
        "amyloid",
        "antibody",
        "promis",
        "comparison",
        "aducanumab",
        "pmn310",
        "showed",
        "significantly",
        "greater",
        "binding",
        "brain",
        "material",
        "ad",
        "patient",
        "toxic",
        "aβ",
        "promis",
        "neuroscience",
        "inc",
        "maturation",
        "pmn310",
        "ongoing",
        "may",
        "result",
        "even",
        "greater",
        "advantage",
        "pmn310",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}